Provided by Tiger Fintech (Singapore) Pte. Ltd.

Erasca, Inc.

2.11
+0.03001.44%
Post-market: 2.110.00000.00%19:36 EDT
Volume:1.55M
Turnover:3.25M
Market Cap:598.54M
PE:-4.66
High:2.15
Open:2.10
Low:2.02
Close:2.08
52wk High:3.31
52wk Low:1.01
Shares:283.67M
Float Shares:167.46M
Volume Ratio:0.89
T/O Rate:0.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4529
EPS(LYR):-0.6913
ROE:-31.16%
ROA:-17.92%
PB:1.61
PE(LYR):-3.05

Loading ...

Erasca Shares Fall After BofA Securities Downgrade

MT Newswires Live
·
Sep 04

Erasca Down Over 14%, On Track for Largest Percent Decrease Since December 2022 -- Data Talk

Dow Jones
·
Sep 04

Erasca Inc : Bofa Global Research Cuts to Underperform From Buy; Cuts Price Objective to $1 From $4

THOMSON REUTERS
·
Sep 03

Erasca Cut to Underperform From Buy by B of A Securities

Dow Jones
·
Sep 03

BofA Securities Downgrades Erasca to Underperform

MT Newswires Live
·
Sep 03

Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

GlobeNewswire
·
Sep 02

Erasca Shares Fall After Downgrade From Morgan Stanley

MT Newswires Live
·
Aug 19

Erasca Cut to Equal-Weight From Overweight by Morgan Stanley

Dow Jones
·
Aug 18

Erasca, Inc. : Morgan Stanley Cuts to Equal-Weight From Overweight

THOMSON REUTERS
·
Aug 18

Erasca Q2 Loss Narrows, Cash Runway Good Until H2 2028

MT Newswires Live
·
Aug 13

Earnings Flash: (ERAS) Erasca Q2 Loss $0.12 Vs FactSet Est. $0.12 Loss

MT Newswires Live
·
Aug 13

Erasca Inc: Sale Agreement Prospectus Covering Offering of up $200 Mln Common Stock That May Be Issued Under Sale Agreement

THOMSON REUTERS
·
Aug 13

Erasca Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 13

Erasca Inc. Unveils Presentation on Their Mission to Erase Cancer and Innovative RAS/MAPK Pathway Strategies

Reuters
·
Aug 13

Erasca Q2 EPS $(0.12) Misses $(0.11) Estimate

Benzinga
·
Aug 13

BRIEF-Erasca Q2 Basic EPS USD -0.12

Reuters
·
Aug 13

Erasca Inc expected to post a loss of 11 cents a share - Earnings Preview

Reuters
·
Aug 09

Mizuho Cuts Price Target on Erasca to $4 From $7, Keeps Outperform Rating

MT Newswires Live
·
Jul 28

Erasca Inc. Conducted Annual Stockholders Meeting

Reuters
·
Jun 27

Erasca Receives US FDA Approval of ERAS-4001 Investigational New Drug Application for Solid Tumors

MT Newswires Live
·
Jun 02